What JMI Laboratories does

JMI Laboratories is a U.S.-based contract research organization specializing in antimicrobial resistance research services for pharmaceutical and biotechnology sponsors developing new antimicrobial drugs. The company operates a CLIA-certified reference microbiology laboratory in North Liberty, Iowa, and is the steward of the SENTRY Antimicrobial Surveillance Program, established in 1997, which monitors global pathogen resistance patterns through a network of 150+ medical centers across 35+ countries, processing approximately 40,000 clinical isolates annually.

Its technology stack combines reference broth microdilution susceptibility testing (CLSI and EUCAST breakpoint analysis) with next-generation sequencing via short-read (Illumina) and long-read (Nanopore) platforms, processed through a proprietary bioinformatics pipeline that performs de novo assembly and identifies resistance/virulence genes, SNPs, and plasmid elements. The company also maintains a characterized biobank of clinical isolates with defined resistance mechanisms used for drug development studies.

JMI generates revenue through six professional service lines billed on a contract basis: antimicrobial surveillance (including SENTRY), drug development support for new investigational compounds, molecular characterization studies, GCLP-compliant Phase I-IV clinical trial microbiology support, microbiome studies (16S and shotgun metagenomics), and medical writing/publication services. Customers include large-cap pharmaceutical companies (Pfizer, GSK, Melinta, Menarini, Paratek, Wockhardt, Nabriva, Scynexis, Spero, Venatorx, Entasis) and approximately ten antimicrobial-focused biotech startups (Amplyx, Amicrobe, BugWorks, Bravos, Forge, KBPbio, Qpexbio, Seluxdx). The company was founded in 2010 and was acquired by Element, a strategic operating company in the life sciences services sector, in 2026.

Name

JMI Laboratories

Legal name

JMI Laboratories

Website

https://jmilabs.com

Company type

Private

Founded year

1997

Operating status

Acquired

Headcount range

101–250 employees

Short description

JMI Laboratories is a U.S.-based CLIA-certified contract microbiology laboratory providing antimicrobial surveillance, drug development, and GCLP clinical trial services to pharmaceutical and biotech sponsors developing new antimicrobial drugs, anchored by the 28-year-old SENTRY global resistance monitoring program.

Ownership category

akta.pro rank

Product category

Contract Microbiology Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industries

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF), Clinical Research & Trial Central Laboratories (HLAFAMAL), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Antimicrobial surveillance services
• Clinical microbiology testing
• Drug development support
• Molecular characterization services
• Clinical trial microbiology

Headquarters

HQ city

North Liberty

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Antimicrobial Surveillance Studies: Contract research services performing surveillance studies for pharmaceutical companies for new drug development and post-marketing monitoring. Clients contract for specific surveillance data such as geography, infection types, or pathogens. Uses a shared platform approach to reduce costs.
2. Drug Development Support: CLIA certified reference microbiology laboratory providing support for development of new investigational compounds including spectrum/potency testing, resistance studies, synergy studies, and NDA application requirements.
3. Molecular Studies: Full molecular characterization of isolates including epidemiological typing, resistance and virulence gene detection through NGS, gene expression, and various typing methods (MLST, antigen typing, SNP analysis, microbiome analysis).
4. Clinical Trial Support (GCLP): GCLP compliant support for bacterial and fungal phase I-IV clinical trials including organism identification, susceptibility testing, culture from clinical samples, epidemiology typing, and NGS for resistance analysis.
5. Microbiome Studies:
6. Medical Writing Services: Publication strategy development, manuscript writing, abstract preparation, peer reviewer responses, page proof approvals, and large-format poster printing with congress logistics support.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

JMI Laboratories is a CLIA-certified reference microbiology contract research laboratory providing antimicrobial surveillance (including the SENTRY Antimicrobial Surveillance Program established in 1997), drug development microbiology support, molecular characterization via next-generation sequencing, GCLP-compliant clinical trial central lab services, microbiome analysis, and medical writing. Services are delivered to pharmaceutical, biotechnology, and clinical research clients for anti-infective development, resistance monitoring, and regulatory submission support.

Product overview

JMI Laboratories operates as a unified services portfolio rather than a single product with modules. The core offering consists of six integrated service lines: Antimicrobial Surveillance (including the flagship SENTRY Antimicrobial Surveillance Program established in 1997), Drug Development, Molecular Studies, Clinical Trial Support, Microbiome analysis, and Medical Writing. The SENTRY program serves as the anchor surveillance platform, supported by specialized laboratory services in molecular characterization, GCLP-compliant clinical trial support, microbiome genetics, and scientific publication assistance. All services leverage the organization's CLIA-certified reference microbiology laboratory and extensive clinical isolate collections from a global network.

Differentiator

Problem solved

Functional benefit

Products and services

• SENTRY Antimicrobial Surveillance Program Long-running global antimicrobial surveillance program tracking resistance trends across bacterial and fungal isolates collected from 150+ medical centers in 35+ countries; provides longitudinal resistance data, susceptibility trend analysis, and peer-reviewed publications for pharmaceutical, biotechnology, and academic clients.
• Antimicrobial Surveillance Custom antimicrobial surveillance studies and resistance monitoring beyond the flagship SENTRY program, supporting pharmaceutical and biotech clients with study design, isolate collection, susceptibility testing, and trend analysis tailored to specific geographies, organisms, or drug candidates.
• Drug Development
• Molecular Studies
• Clinical Trial Support
• Microbiome
• Medical Writing

Quantifiable outcome

• 40,000 clinical isolates processed annually through global surveillance network
• +2 more outcomes

Named customers21 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• elementflagshipStrategic or Co-development PartnerJMI Labs is now part of element, a larger organization. This acquisition represents a significant strategic integration where JMI operates under the element corporate umbrella while continuing to provide antimicrobial surveillance and drug development services.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• International Health Management Associates (IHMA): IHMA is a microbiology reference laboratory specializing in antimicrobial resistance surveillance and antibacterial/antifungal drug development services for pharma clients — the closest functional analogue to JMI's SENTRY-based offerings. Directly competes for the same antimicrobial surveillance and drug-development study budgets.

Broad incumbents

• Eurofins Scientific: Global CRO/lab services conglomerate with microbiology, pharmaceutical testing, and central lab capabilities serving similar pharma/biotech sponsors. Overlapping in antimicrobial and clinical-trial microbiology, though Eurofins operates across many testing verticals rather than specializing in AMR surveillance.
• Charles River Laboratories: Large CRO offering discovery, safety assessment, and microbiology services to pharmaceutical clients; comparable end-customers and antimicrobial development workflow overlaps, though Charles River spans the full preclinical-to-manufacturing CRO spectrum.
• Labcorp Drug Development (formerly Covance): Major central laboratory and clinical trial services provider supporting pharma R&D across many therapeutic areas including infectious disease; comparable sponsor base and clinical-trial support capabilities, but vastly broader service portfolio than JMI.
• IQVIA: Global CRO and clinical trial services provider with broad infectious-disease trial support; competes for similar pharma R&D budgets and trial-related central lab work, though IQVIA's services span clinical, commercial, and real-world evidence far beyond microbiology.
• PPD (Thermo Fisher Scientific): Global CRO providing clinical development and central laboratory services to pharmaceutical sponsors; overlapping in microbiology/lab support for infectious disease trials, though PPD's portfolio extends well beyond antimicrobial-focused work.
• Q2 Solutions: Central/clinical trial laboratory services provider (IQVIA/Quintiles joint venture history) supporting pharma trial sponsors; comparable in providing regulated trial-laboratory services, though broader therapeutic focus than antimicrobial-focused JMI.

Others

• bioMérieux: Leader in in-vitro diagnostics and microbiology testing products; serves overlapping pharmaceutical and clinical customers in microbial identification and antimicrobial susceptibility testing, though positioned as an instrument/reagent supplier rather than a reference lab service provider like JMI.
• Wockhardt Bio Pharma: Antimicrobial-focused pharmaceutical company and existing JMI client (per provided customer list); represents an adjacent customer/peer relationship, as in-house surveillance capabilities of large antimicrobial sponsors could become competitive over time.

Emerging players

• Microbiologics: Provider of biological reference materials, including characterized microbial isolates and controls for antimicrobial resistance research; an emerging player in the broader AMR research supply chain serving overlapping pharmaceutical and academic customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/jmilabs
• LinkedInlinkedin.com/company/jmi-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JMI Laboratories